What is the W22 pill used for?: A Comprehensive Guide to Buprenorphine/Naloxone
•
4 min read
Medication-assisted treatment (MAT) is a proven, evidence-based approach that can increase the chances of long-term recovery for those with opioid use disorder (OUD). So, what is the W22 pill used for? It is a sublingual tablet containing buprenorphine and naloxone, prescribed to help manage opioid dependence by reducing cravings and suppressing withdrawal symptoms.
Quick Summary
The W22 pill is a white, round, sublingual tablet containing buprenorphine and naloxone. It is used for the maintenance treatment of opioid use disorder as part of a larger treatment plan that includes counseling and therapy.
Key Points
Combination Drug: The W22 pill contains a combination of buprenorphine and naloxone.
Treatment for OUD: Its primary purpose is for the maintenance treatment of opioid use disorder (OUD).
Abuse Deterrent: The naloxone component is included to deter misuse through injection, as it can cause immediate withdrawal symptoms if injected.
Sublingual Administration: It is a tablet placed under the tongue to dissolve completely and should not be swallowed.
Part of Holistic Treatment: The medication is most effective when used as part of a complete treatment program including counseling and psychosocial support.
Controlled Substance: The W22 pill is a Schedule 3 controlled substance, requiring careful clinical monitoring and prescription management.
In This Article
Information is for general knowledge and should not be taken as medical advice. Consult with a healthcare provider.
## What is the W22 Pill?
The W22 pill is a combination medication containing Buprenorphine Hydrochloride and Naloxone Hydrochloride. It is manufactured by Accord Healthcare Inc. and is available by prescription only. The pill is white, round, and has the imprint 'W22' on one side. This particular version is a sublingual tablet, which means it is designed to be dissolved under the tongue for proper absorption. The 'W22' imprint signifies a specific formulation of buprenorphine and naloxone.
### The Role of Buprenorphine and Naloxone
This medication combines two distinct active ingredients to achieve its therapeutic effect:
* **Buprenorphine:** As a partial opioid agonist, buprenorphine binds to and partially activates the opioid receptors in the brain. This activation helps to reduce opioid cravings and withdrawal symptoms, but does so with a much lower risk of euphoria and respiratory depression compared to full opioid agonists like heroin or oxycodone. This partial agonism is key to stabilizing a patient and preventing misuse of other, more dangerous opioids.
* **Naloxone:** This ingredient is an opioid antagonist, meaning it blocks opioid receptors. It is included in the pill as an abuse deterrent. When the W22 pill is taken correctly under the tongue, the naloxone has very little effect on the body. However, if the medication is misused by injection, the naloxone is activated, causing immediate and intense opioid withdrawal symptoms. This aversive effect is intended to discourage injecting the medication and thereby prevent potential abuse.
## The Use of the W22 Pill for Opioid Use Disorder
The primary indication for the W22 pill is the treatment of opioid use disorder (OUD), previously known as opioid dependence. It is an integral part of a comprehensive treatment program known as Medication-Assisted Treatment (MAT). This program emphasizes a holistic approach to recovery, combining the pharmacological support of the medication with counseling and behavioral therapies. The goal of using the W22 pill is not to simply replace one opioid with another, but to help individuals manage their recovery by reducing the physical symptoms and cravings that can lead to relapse.
### Administration
To ensure efficacy and minimize risks, the W22 pill must be taken exactly as prescribed:
1. Place the tablet under the tongue and allow it to fully dissolve.
2. Do not chew, crush, or swallow the tablet, as this will prevent proper absorption.
3. Avoid talking while the tablet is dissolving to ensure it stays in place.
4. Do not eat or drink anything until the tablet has completely dissolved.
5. Follow the instructions provided by your healthcare provider.
The initiation phase of treatment (induction) is typically performed under the supervision of a healthcare provider before unsupervised maintenance therapy begins.
## Side Effects and Safety Information
Patients taking the W22 pill may experience a range of side effects. It is crucial to be aware of these and to communicate any serious or persistent side effects to a doctor.
### Common side effects
* Headache
* Nausea and vomiting
* Constipation
* Sweating
* Drowsiness or fatigue
* Insomnia
* Withdrawal symptoms (especially if the medication is stopped abruptly)
* Oral numbness or irritation
### Serious side effects
* **Respiratory Depression:** This is a life-threatening risk, especially when mixed with alcohol, benzodiazepines, or other central nervous system (CNS) depressants.
* **Liver Problems:** In rare cases, liver damage can occur. Symptoms include dark urine, yellowing of the skin or eyes (jaundice), and abdominal pain.
* **Adrenal Insufficiency:** A condition where the adrenal glands do not produce enough cortisol. Symptoms include nausea, vomiting, dizziness, and fatigue.
* **Serotonin Syndrome:** A rare but serious condition caused by excess serotonin in the body. Symptoms include anxiety, restlessness, muscle twitching, and rapid heartbeat.
* **Dental Problems:** Cases of dental caries and tooth loss have been reported with transmucosal buprenorphine products. Regular dental checkups are recommended.
## W22 Pill vs. Other Sublingual Buprenorphine/Naloxone Products
Several generic and brand-name products contain the same combination of buprenorphine and naloxone. The primary differences often relate to the formulation (tablet vs. film), available strengths, and excipients (inactive ingredients).
| Feature | W22 Sublingual Tablet | Suboxone Sublingual Film | Zubsolv Sublingual Tablet |
| :--- | :--- | :--- | :--- |
| **Manufacturer** | Accord Healthcare Inc. | Indivior | Orexo |
| **Formulation** | White, round sublingual tablet | Orange, hexagonal sublingual film | White, triangular sublingual tablet |
| **Available Strengths** | Various strengths | Multiple strengths | Multiple strengths |
| **Key Benefit** | Generic option; may be a lower-cost alternative to brand names. | Dissolves faster; some patients prefer the discreet film. | Higher bioavailability; potentially smaller tablets needed for comparable effect. |
## Conclusion
The W22 pill, a combination of buprenorphine and naloxone, is an effective and widely used medication for the treatment of opioid use disorder. It works by managing withdrawal symptoms and cravings, helping to stabilize individuals on their path to recovery. However, like any prescription medication, it carries risks, particularly when misused or combined with other substances. The W22 pill is most effective when integrated into a comprehensive treatment plan that includes ongoing counseling and support. Patients must adhere to their doctor's prescribed regimen and administration instructions to ensure safety and maximize the therapeutic benefits. For more information on medication-assisted treatment and opioid recovery resources, visit the [Substance Abuse and Mental Health Services Administration (SAMHSA)](https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/buprenorphine).
Frequently Asked Questions
The W22 pill is a generic version of the combination medication buprenorphine and naloxone. It is manufactured by Accord Healthcare Inc..
Buprenorphine, a partial opioid agonist, reduces cravings and withdrawal symptoms, while naloxone, an opioid antagonist, is included to deter misuse. The naloxone triggers withdrawal if the pill is injected, but has little effect when taken as prescribed under the tongue.
No, the W22 pill is a sublingual tablet and must be placed under the tongue and allowed to dissolve completely. Chewing or swallowing the tablet reduces its bioavailability and effectiveness.
Abruptly stopping the medication can cause withdrawal symptoms. Treatment should be discontinued gradually under a doctor's supervision to minimize discomfort.
No, the W22 pill is not intended as an analgesic for treating pain. It is used specifically for the maintenance treatment of opioid dependence.
Mixing the W22 pill with other CNS depressants, like benzodiazepines and alcohol, can lead to severe and potentially fatal respiratory depression. You should inform your doctor about all medications you are taking.
The W22 pill can cause drowsiness and dizziness, especially during the initial stages of treatment and dose adjustments. Patients should avoid driving or operating heavy machinery until they understand how the medication affects them.
Cases of severe dental problems have been reported with transmucosal buprenorphine products. Patients should maintain regular dental checkups and rinse their mouth with water after the tablet has dissolved.
